Cefepime

Drug Profile

Cefepime

Alternative Names: Axepim; BMY 28142; Maxcef; Maxipime

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bacterial infections; Febrile neutropenia; Intra-abdominal infections; Respiratory tract infections; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 30 Sep 2010 Elan stops distributing cefepime in USA
  • 01 Nov 2004 A study has been added to the Bacterial Infections therapeutic trials section
  • 16 Sep 2004 Registered for Febrile neutropenia in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top